Evidence map›Paper›PMID 29166233›Full record

ArticleThe New England journal of medicine2017

Reduction of Loa loa Microfilaremia with Imatinib - A Case Report.

Elise M O'Connell, Thomas B Nutman

Registry-linked trialAbstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02644525 (A Double-blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Efficacy and Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02644525 phase2terminatednot on this mapstarted 2019, after this paper: background citation

A Double-blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Efficacy and Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2019 to 2021Enrolled20ConditionsLoiasisArmsImatinib Mesylate, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Review
  4. Targeting Kinases inFrontiers in veterinary science · 2020
    Article
  5. Answer to August 2019 Photo Quiz.Journal of clinical microbiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Elise M O'ConnellNational Institute of Allergy and Infectious Diseases, Bethesda, MD oconnellem@niaid.nih.gov.
Thomas B NutmanNational Institute of Allergy and Infectious Diseases, Bethesda, MD oconnellem@niaid.nih.gov.

Funding

Clinical And Therapeutic Studies Of Human Filariasis and Related DiseasesZIAAI000439 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2009 to 2025
$14.8M
Biomarkers and host-parasite interactions in neurocysticercosis and other parasitic infectionsZIAAI001234 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NUTMAN, THOMAS · 2018 to 2025
$2.5M
Clinical/Therapeutic Studies Of Filariasis &Related DisZ01AI000439 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI NUTMAN, THOMAS B · 1985 to 2008
$800k
Intramural NIH HHS Z01 AI000439
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Administration, OralAdultAnimalsAnthelminticsFemaleHumansImatinib MesylateLoaLoiasisMicrofilariaeAnthelminticsImatinib Mesylate

Identifiers

PMID29166233
PMCPMC5774668

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.